Erenumab and Galcanezumab for Chronic Migraine Refractory to OnabotulinumtoxinA: A Real-World Comparative Study

Puntos clave

• The study aims to compare the effectiveness of erenumab and galcanezumab in reducing chronic migraine frequency in patients resistant to onabotulinumtoxinA.
• Conducted a real-world comparative study
• Included patients with chronic migraine refractory to onabotulinumtoxinA
• Assessed migraine frequency and triptan use before and after treatment with both interventions
• Both erenumab and galcanezumab led to sustained reductions in migraine frequency
• High responder rates were observed for both treatments
• Triptan use decreased significantly among patients receiving anti-CGRP monoclonal antibodies

Resumen